APLIFOTCHealthcare · Biotechnology

Appili Therapeutics Inc.

$0.02+0.00%(+$0.00)

TickerSpark Score

56/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLIF research report →

52-Week Range32% of range

Low $0.01

Current $0.02

High $0.03

Companywww.appilitherapeutics.com

Appili Therapeutics Inc. , a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.

CEO: Donald D. Cilla Jr. Pharmd
IPO: 2021
Employees: 8
HQ: Halifax, NS, CA

Price Chart

+33.33% · this period

Valuation

Market Cap: $2.05M
P/E: -0.65
P/S: 9.33
P/B: -0.12
EV/EBITDA: -8.91
Div Yield: 0.00%

Profitability

Gross Margin: 96.74%
Op Margin: -1517.29%
Net Margin: -1434.78%
ROE: 19.73%
ROIC: 79.76%

Growth & Income

Revenue: $100.44K · -87.86%
Net Income: $-2,624,692 · 30.58%
EPS: $-0.02 · 30.77%
Op Income: $-190,839
FCF YoY: 134.74%

Performance & Tape

52W High: $0.03
52W Low: $0.01
50D MA: $0.01
200D MA: $0.01
Beta: -0.30
Avg Volume: 24.04K

Get TickerSpark's AI analysis on APLIF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime